Thermo Fisher rises after firm links proteomics to large Singapore genetics study

What happened

Thermo Fisher (TMO) rose 3.4% on October 5, 2026, after saying its proteomics technologies helped identify more than 2,500 previously unreported genetic–protein associations in the PRECISE-SG100K study, Business Wire reported. The stock opened 1.0% below the previous close and finished at $676.76, with trading volume of 0.9 times its 20-day average. The S&P 500 rose 0.7% and the healthcare sector median rose 0.8%, so the stock outperformed its sector by 2.6 percentage points. The company had a market value of $242.11 billion.

How big was the move

The 3.4% gain was 1.8 times a typical daily move for the stock, classifying it as a large, mostly company-specific move and suggesting the company news was the likely driver. Market sensitivity was modest, with a beta of 0.74, indicating the stock tends to move less than the market. Over the last five sessions the stock fell 0.3% while the S&P 500 rose 1.2%, underscoring that the October 5 move diverged from the market’s short-term direction. In the past five years the stock had 34 sessions with a gain of at least 3.4%; twenty trading days later the median result was a gain of 3.7%, and 21 of 34 were higher.

The technical picture

The stock sat 1.0% below its 52-week high and was trading above key moving averages, 4.2% above its 20-day moving average, 9.2% above its 50-day moving average and 24.6% above its 200-day moving average. The 50-day average was above the 200-day average, a sign of an established uptrend, and the stock had spent 52 consecutive trading days above the 200-day average. Short-term momentum was neutral with a 14-day Relative Strength Index of 65. Performance showed gains of 9.4% over one month, 31.0% over three months and 28.9% over one year, the latter beating the S&P 500 by 13.2 percentage points. Volatility was elevated at 29% annualized over 60 days, higher than 64% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 27, 2026, Thermo Fisher reported revenue of $46.34 billion, which grew 7.2% from a year earlier. Diluted earnings per share for that period were $18.59, up 7.6% year over year. Gross margin was 41.0% versus 40.4% a year earlier, while operating margin was 18.0% compared with 18.4% a year earlier. Free-cash-flow margin stood at 15.8% and return on invested capital was 7.6%. The balance sheet showed net debt of 3.5 times EBITDA and share count decreased by 1.9% over one year, indicating continued buybacks.

Valuation was rich: price to trailing earnings stood at 36.4 times trailing earnings, higher than 86% of its own readings over the past five years, with a five-year median of 30.9 times earnings. Price to forward earnings was 27.0 times expected earnings and free-cash-flow yield was 3.0%. Within sector-ranking scores the stock posted a Value score of 61 (Neutral), Growth 46 (Neutral), Quality 58 (Neutral), Momentum 81 (Strong), Revisions 63 (Neutral) and Stability 81 (Strong). The sharp momentum and solid fundamentals help explain investor interest despite a valuation that is generous by historical standards.

Earnings and analyst expectations

Thermo Fisher last reported on July 23, 2026, posting earnings per share of $6.03 against $5.72 expected, 5.4% above estimates. The company had beaten estimates for 12 consecutive quarters, with an average surprise of 4.0% above estimates over the last four reports. Typical two-day reactions after recent reports showed the stock rose 1.5%. The next scheduled report is October 21, 2026. Analysts covering the company total 43, with a consensus rating of Buy and 84% of ratings at Buy or higher. The consensus price target was $631.42, 6.7% below the closing price of $676.76.

What to watch

• October 21, 2026: next earnings report date.
• Business Wire report: the PRECISE-SG100K study identified more than 2,500 previously unreported genetic–protein associations.
• Trading volume relative to 20-day average: 0.9 times its 20-day average on October 5, 2026.
• Valuation relative to history: price to trailing earnings at 36.4 times, higher than 86% of five-year readings.
• Balance sheet leverage: net debt of 3.5 times EBITDA.